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Treatment of Hyperthyroidism from the
Autonomous Multinodular Goiter
by

J. Martin Miller, M.D.' and Richard E . Weber, M.D.'
and
Melvin A. Block, M.D.'

47 patients with large multinodular goiters und "itott-Clraves" hyperthyroidism
were treated surgically or given radioiodine therapy. The severity of the disease
and cardiac complications were comparable in each group. Results favor subtotal thyroidectomy if the disease is other than mild or if atrial fibrillation is
present.

Autonomous hyperfunction of the thyroid occurs in two distinctly different anatomical settings. The first is the solitary nodule with one dimension of at least 3 cm.
and little radioiodine uptake or palpable abnormality in the remainder of the gland. The
second is the long-standing multinodular gland weighing in excess of 50-60 grams in
which autonomous function apparently develops subsequent to the increased thyroid
mass. Radioiodine uptake on the scintigram is usually found in many areas rather than
related to a single palpable nodule. Management of the former has been adequately
discussed and will receive no further attention here. Surgery has been traditional for
treating hyperthyroidism of the large autonomous goiters. This approach has recently
been reaffirmed without specific details by such experienced thyroid clinicians as
McCullough' and Silver.^ Radioiodine therapy has been used increasingly for hyperthyroidism in patients with multinodular goiter but it is difficult to evaluate this treatment
because Graves" disease may be superimposed on an endemic or sporadic goiter.
Rather than evaluate the two therapeutic approaches by comparison of patients from
diverse sources, we have observed a small but carefully studied group in which the
diagnosis was made by uniform standards and all aspects of the disease were comparable in the "'I-treated and surgically-treated patients.
'Division of Endocrinology, Henry Ford Hospital
'Department of General Surgery, Henry Ford Hospital
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Clinical Criteria

From 1956 through 1965, 47 patients met our criteria for toxic autonomous multinodular goiter. A clinical diagnosis of mild to moderate hyperthyroidism was made by
the findings of tachycardia and precordial overactivity, often with dyspnea, atrial
fibrillation, or congestive heart failure, in combination with moderate weight loss and
tremor in a patient over 40 with a 50 gram-plus nodular goiter present for over 10
years. None had measurable exophthalmos, congestive oculopathy, or the neuromuscular
excitability characteristic of Graves' disease.
Clinical diagnosis was confirmed by a proteinbound iodine (PBI) of over 8 meg %
(34 of 38) or by a basal metabolism rate (BMR) of more than -|-25 (17 of 19) in
patients without cardiac failure. Disappearance of all abnormal findings after definitive
therapy was considered the s'lne qua non for the diagnosis of the hyperthyroidism.
The 24-hour "'I-uptake was below 55% in 43 untreated patients, and did not
decrease after administration of 75 meg of liothyronine for five days in the 29 cases
with uptakes below 40%. Two of the I I patients with uptakes below 20% had a
history of iodide ingestion three to six weeks prior to the test. Ten units of thyroid
stimulating hormone (TSH) increased the absolute uptake of radioiodine from 15 to
70% in 23 of 24 attempts. Long-acting thyroid stimulator* was not detectable in the
serum of the seven cases in which it was assayed. Although it was present in five of
five control cases of Graves' disease, the absence of this hormone was not considered
diagnostic.
In 37 patients the scintigram revealed a generalized patchy uptake of radioiodine.
Repeat scintigrams after TSH in 10 of these demonstrated a sufficient area of suppressed tissue to establish the diagnosis in only two patients. In three additional
patients, however, the original uptake was prominent in a single area, and in these the
post-TSH scintigram was diagnostic.
The pathologic examination of the surgical specimens in no instance suggested
Graves' disease nor did the single or double isotope autoradiographs done on seven
patients.
Table I
Comparative Pretreatment Clinical Data
Surgery
Average Age
Average PBI mcg%
Gland Weight
Atrial Fibrillation
Congestive Heart Failure
Hypertensive Heart Disease with
Left Ventricular Hyperthrophy
'assayed at Bio-Science Laboratories, California
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61 (46-76)
10.4 (16 of 21)
170 gms.
6
4

190 gms.
5
2

5

3

65 (55-79)
10.2 (22 of 26)

TREATMENT OF HYPERTHYROIDISM
Choice of Therapy
A total of 21 patients were operated upon and 26 were treated with " ' I . Both
groups were comparable as to age, severity of the disease, size of the goiter, and
incidence of cardiac complications (Table I ) . In addition to the conditions listed,
one surgically treated patient had an interventricular septal defect. Three radioiodine
treated patients had obstructive symptoms at the thoracic inlet and one had portal
cirrhosis.
The selection of " ' I therapy in 21 cases represented an acknowledgment of the
usual morbidity from surgery in patients of this age group rather than a concern for
possible increased mortality related to an associated disease. In five patients, surgery
was contraindicated because of the severity of the hyperthyroidism itself or because of
concomitant disease of the heart or liver. The three patients with obstructive symptoms
were in this category, and radioiodine was originally intended for prc-opcrativc control
of the hyperthyroidism.
Pretreatment Medication
In 10 patients surgery was performed without preparation with thiourea drugs
and an average PBI of 8.7 meg. per cent reflected the clinical mildness of the disease.
One patient received iodides alone without effect and one had only prophylactic glucocorticoid therapy. Eleven patients with an average PBI of 12.5 meg. per cent received
from 60 to 100 mg. of methimazole daily for three to 12 weeks. In three the drug
had little effect but two of these were receiving iodides simultaneously. Seven of this
group received parenteral corticoids pre- and postoperatively. (100 mg. of cortisone
acetate I . M . the evening before surgery and every twelve hours in doses of 50-100 mg.
for the next two days. 100 mg. of hydrocortisone were given I.V. during the operation.)
No patient who received " ^ I was pretreated because of the severity of the hyperthyroidism. Six patients had been given methimazole until a decision was made regarding definitive therapy, or because of an initial low radioiodine uptake. In 16 instances
the patient was treated with " ^ I when the uptake had been increased by TSH. In three
cases the PBI increased from 3 to 10 meg. per cent after TSH but in two the effect
may have been partially related to the subsequent radioiodine therapy.
Resnlts
Surgery
All 21 surgically treated patients were euthyroid by the tenth post-operative day.
All were discharged from the hospital by this time with the exception of one patient
who was simultaneously treated for hyperparathyroidism. Significant postoperative
morbidity was encountered in four patients. One patient, who had no definitive preoperative preparation had tachycardia (160), restlessness, sweating, and increased skin
temperature on the first postoperative day. These findings disappeared 36 hours following steroid therapy. Another patient without preparation became restless and developed atrial fibrillation 30 hours postoperatively. She responded promptly to temporary digitalization. A third patient, incompletely prepared with methimazole because
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of a drug allergy, began on the first postoperative day to fibrillate and exhibited restlessness, sweating and a warm skin. During five days of treatment with steroids and
digitoxin, all these symptoms subsided. The other reaction (fourth patient) was one of
transient cerebral ischemia on the sixth postoperative day.
All patients with preoperative atrial fibrillation converted spontaneously to normal
sinus rhythm. Four of the 21 patients subsequently have been judged hypothyroid and
are receiving thyroid replacement therapy.
Radio-Iodine

Therapy

Ten patients were made euthyroid by a single dose of " ' I and ten others required
two doses. The PBI, thyroid size, initial dose, and pretreatment medication are listed
in Table I I . The patients who became euthyroid following a single dose did so
in from two to four months. Those requiring retreatment received the second dose
between three and six months after the first and became euthyroid in a total of six to 15
months (average 8.7). Seven patients were given TSH before the second therapy since
the average uptake at this time was only 1 1 % .
Morbidity in this group consisted of a moderately severe radiation thyroiditis, mild
obstructive symptoms from 20 units of TSH in a patient with retromanubrial goiter, a
probable mild exacerbation of the disease with nausea and vomiting, and a posttreatment psychosis. An additional patient with prominent obstructive symptoms experienced some progression of them during the first week after 30 millicuries of radioiodine
had been given. In one patient with a somewhat localized radioiodine uptake and pretreatment methimazole, hypothyroidism was evident at three months. Of the three
patients who were fibrillating before therapy, one converted spontaneously, one with
quinidine, and one with radioiodine when the PBI was 5.5 meg. per cent six months
after the initial therapy. Over a period of four years the PBI of the last patient rose
from 5.6 to 8 meg. per cent, and she again became clinically thyrotoxic with atrial
fibrillation. In this case, 25 millicuries of radioiodine restored the euthyroid state and
normal sinus rhythm. Fibrillation recurred two years later at which time the PBI was 5.2.
Additional radioiodine was without effect.
In two patients, goiters of over 75 grams remain three and six years after treatment
with two doses of radioiodine: they are euthyroid and the PBI levels are over 6 meg.
per cent. One patient became euthyroid but was subsequently operated upon because
the referring surgeon feared cancer. One hundred grams of tis.sue were removed and
hypothyroidism developed.
Table II
Comparative Data on 20 Patients Rendered Euthyroid With Radioiodine.

One Dose (10)
Two Doses (10)

Av. PBI

Gland Wt.

Initial Dose

TSH or
Methimazole

8.8 ugm%
11.5 iigm%

135
140

36 mc (20-50)
34 mc (20-50)

7
4
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Four patients treated with a single 50 millicurie dose of radioiodine were lost
to followup. Three had received TSH or methimazole. One died of cirrhosis, still
hyperthyroid at five months. Another failed to return but was observed elsewhere to
be still thyrotoxic after two months and the goiter remained large. The other two were
thyrotoxic with large goiters at four months and were not seen thereafter.
Two patients died within eight days of the therapy and are described in more
detail. The first was a 63-year-old woman, mildly thyrotoxic from a very large goiter.
She had been treated against the advice of the thyroid consultant with 60 mg. of
methimazole daily for four months. The hyperthyroidism and the original BMR of
4-50 were unchanged by therapy, but her congestive heart failure and atrial fibrillation
were controlled by digitalis and diuretics. The 24-hour uptake of radioiodine was 50%
and 50 millicuries of "T were administered. In 24 hours the patient had an apparent
exacerbation of the disease and died 12 hours later of infarction of the bowel from
an embolus to the superior mesenteric artery. The thyroid weighed 650 grams.
The second patient, a 64-year-old woman with hyperthyroidism for one year, had
a large cervical thyroid with a huge intrathoracic component extending to the level
of the left atrium. She had azygos vein obstruction, tortuous thoracic veins, a right
pleural effusion, and atrial fibrillation. The protein-bound iodine was 11.3 mcg.%, and
the 24-hour " ' I uptake 52%. The surgical consultant suggested medical therapy. The
gland was estimated to weigh in excess of 1000 grams and 100 millicuries of " ' I were
administered. No change in the thyroid status was evident after therapy, but on the
sixth day a cerebral vascular accident resulted in death within 48 hours. The proteinbound iodine on day 6 was 11.4 mcg.%. Permission for autopsy was refused.
Comments
Our experience reaffirms the efficiency of surgical therapy inasmuch as the
elapsed time from initiation of treatment to the onset of the euthyroid state averaged
five weeks. The length of the preoperative preparation, not always optimal, reflected
the severity of the disease. Although the disciples of Henry Plummer have taught that
thyroid storm does not follow the surgical treatment of toxic autonomous goiter, two
of the reactions observed were in all ways similar to those seen after surgery for
poorly controlled Graves' disease. Our use of prophylactic glucocorticoids in some
cases was a compromise between antithyroid drug preparation and no preparation at
all, and was based on the early experience of Szilagyi in preparing patients with Graves'
disease for surgery.' From this limited experience we cannot attest to the value of
steroids and would favor the more frequent use of large doses of the thiourea drugs.
In patients with a low radioiodine uptake, however, the response to the antithyroid
drugs is not as satisfactory as in treating toxic diffuse goiter, because hormone synthesis
would not be rapid at that time. The results in our four cases do not support the
preoperative use of iodides, although Green and Ingbar observed that they slowed
thyroxine release from the autonomous nodule." We have also seen iodide therapy
"produce" thyrotoxicosis in patients with autonomous multinodular goiters (Jod-Basedow
phenomenon).
,S4
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The extent of the surgery virtually precludes recurrence of this disease in our
patients, most of whom were over 50. In fact, the hypothyroidism observed represented
the over-enthusiasm of the surgeon for removing all abnormal tissue when the gland
was composed of nothing else. Age, thyrotoxicosis, and the associated cardiac states
were factors in these patients which made them less than optimal surgical risks. Such
a small series would scarcely justify conclusions relative to morbidity or mortality, but
the results would encourage continuation of this therapeutic approach.
The use of "T in the treatment of patients with toxic autonomous goiter has been
retarded by a poor understanding of the pathophysiology of the disease, the large doses
of radioiodine required, the long therapeutic interval, and the fear of associated thyroid
cancer. Despite this, the known morbidity of surgery in such patients has led to an
increasing use of radioiodine. From the acknowledgment by Cooke of the effectiveness
of "T as a substitute treatment in 1955,= the indications for its use have been liberalized,
and it is now recommended by Volpe for all cases.' Even in the minds of surgical observers,' the possibility of cancer in these " ' I treated glands is not considered sufficient to
militate against this therapy. In the present series, selection of the dosage reflected, on
one hand, the findings of Cooke as to the effectiveness of a 50 millicurie dose,'
and on the other, the necessity for hospitalization when over 30 millicuries were administered. The need for multiple doses correlated better with the severity of the disease
than with the size of the initial dose. The average time required to achieve a euthyroid
state was six months, but this estimate did not include the two patients improved following additional radioiodine therapy for recurrent thyrotoxicosis and/or atrial fibrillation. Likewise, we did not include the other patients mentioned who continued to
have goiters of appreciable size, and who may need retreatment. The average total dose
required initially to achieve the euthyroid state was 46 millicuries (20-100 mc).
The use of TSH prior to initial or subsequent doses of radioiodine requires special
comment. Skillern eight years ago recommended its use on an empiric basis despite
the theoretical objection that it would preferentially stimulate suppressed tissue.'
Our subsequent experience has confirmed his judgment and double isotope autoradiographic studies' have established a theoretical basis for this approach. The effect of
methimazole was similar to that of TSH, in that when the euthyroid state was achieved,
endogenous TSH would stimulate previously suppressed tissue. The known effect of
methimazole in decreasing the sensitivity of the gland to radioiodine was not evident
in our series.
Patients who never returned after " ' I therapy would probably not have returned
for thiourea preparation for surgery. For them, immediate surgery would have been
an appreciable risk. In the case of two patients who died, it was this surgical risk that
led to the choice of " ' I as a more decisive approach rather than increased or initial
antithyroid drug therapy. Whether the treatment was responsible for their deaths is
unknown. The findings of Simone et al'" that increased antihemophilic factor is present
in thyrotoxicosis suggests that a mild exacerbation of the disease from " ' I might have
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increased this factor and contributed to the occurrence of thrombosis or embolism as
the mortal event. Of the four deaths reported by Volpe to have occurred within one
week after " ' I therapy, two were related to vascular obstruction.'
In a patient with mild thyrotoxicosis and no atrial fibrillation, myocardial or
coronary insufficiency, the persistence of symptoms or their treatment with antithyroid
drugs for three to six months would seem to be no contraindication to "T therapy.
In these patients one dose should suffice and failure to eradicate a goiter completely
in a patient who has lived with it for 10 years or more is of little consequence. If the
degree of hyperthyroidism or the presence of cardiac complications indicates the need
for prompt, definitive therapy, and " ' I is chosen, this should be followed by the use
of anti-thyroid drugs. Surgical removal then can be accomplished without delay if the
" ' I response is inadequate. This can be anticipated if appreciable reduction in the size
of the gland is not observed in a patient with generalized uptake on scintigram. I n using
" ' I therapy, consideration must be given to the availability of the euthyroid patient for
careful followup if an appreciable goiter remains. Autonomous hyperfunction may
arise or increase in areas not destroyed by the initial therapy.
It is unknown to what extent the hemopoietic organs have been affected by the
relatively large dose of ' " ' I used in treating autonomously functioning goiters. Most
reassuring current data on leukemia have been accumulated for Graves' disease, for
which a considerably smaller dose of "T has been given." On the other hand our
maximum total dose of 100 mc is approaching the smallest dose (261 mc) suspected
of being leukemogenic in the treatment of thyroid cancer.^' As surgical therapy
has its seemingly unavoidable morbidity, so radioiodine therapy may be found to
have inherent morbidities with the larger amounts of radiation. A meaningful assessment will require the pooled experience of many therapists. As of now, the treatment
of autonomous hyperfunctioning goiter requires discriminating judgment as to which
approach or combination of therapies is best for a given patient.
Summary
Twenty-one patients with toxic autonomous multinodular goiter were rendered
euthyroid by subtotal thyroidectomy in an average time of five weeks. Postoperative
reactions probably were related to inadequate preparation for the surgery rather than
the presence of associated cardiac disease. The same number of patients was successfully
treated by radioiodine. The average dose was 46 millicuries and an average of six
months elapsed before the euthyroid state was achieved. Two patients died within a
week of treatment and four others remained hyperthyroid until lost to followup. The
need for multiple doses correlated better with the severity of the disease than with the
size of the treatment dose. Our observations suggest that " ' I alone is to be preferred
only for the patient with mild thyrotoxicosis and no cardiac complications which require
prompt control of the disease. The patient with concomitant disease which substantially
increases the risk of eventual surgery will probably continue to be treated with radioiodine. Our series, however, does not contain a patient successfully managed in this
fashion.
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